Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC

多中心介入性淋巴管平滑肌瘤病早期疾病试验（MILED）-CCC

• 批准号: 10219338
• 负责人: Francis Xavier McCormack
• 金额: $ 53.66万
• 依托单位: UNIVERSITY OF CINCINNATI
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-20 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10219338
• 关键词: Address; Adverse event; Aromatase Inhibitors; Benign; Biological Markers; Cells; Cessation of life; Charge; Chronic; Chronic Myeloid Leukemia; Clinic; Clinical; Communities; Cyst; Data; Data Coordinating Center; Department of Defense; Development; Diffuse; Disease; Disease Progression; Dose; Eligibility Determination; Enrollment; FDA approved; FRAP1 gene; Florida; Foundations; Fright; Gases; Genes; Gleevec; Goals; Growth; Growth Factor; Impairment; Information Dissemination; Infrastructure; International; Intervention; Investments; Japan; Knowledge; Lead; Life; Lung; Lung diseases; Lymphangiogenesis; Lymphangioleiomyomatosis; Magnetic Resonance Imaging; Measures; Molecular; Mutation; Neoplasm Metastasis; Neoplasms; Pathogenesis; Pathway interactions; Patient Participation; Patients; Performance; Pharmaceutical Preparations; Phase; Placebos; Pleural effusion disorder; Pneumothorax; Prognostic Marker; Pulmonary Function Test/Forced Expiratory Volume 1; Pulmonary function tests; Quality of life; Randomized; Recurrence; Respiratory Failure; Safety; Serum; Severities; Signal Transduction; Sirolimus; Site; Smooth Muscle; Smooth Muscle Myocytes; Source; Time; Toxic effect; Tuberous Sclerosis; Universities; Vascular Endothelial Growth Factor D; Vital capacity; Woman; advanced disease; airway obstruction; biomarker discovery; data management; diagnostic biomarker; disability; improved; lung injury; lung preservation; lung volume; mTOR Inhibitor; mTOR inhibition; middle age; mortality; neoplastic; placebo group; prevent; primary endpoint; programs; pulmonary function; pulmonary function decline; randomized placebo controlled trial; rate of change; recruit; respiratory; secondary endpoint; side effect; targeted treatment

Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (The MILED Trial) Project Summary Lymphangioleiomyomatosis (LAM) is low-grade metastasizing neoplasm of women, driven by activating mutations in the mTOR pathway that result in cystic destruction of the lung. The benign appearing, mutation bearing smooth muscle-like LAM cells that infiltrate the lung arise from an unknown source and execute a program of matrix remodeling that leads to cyst formation, recurrent pneumothorax, chylous pleural effusion and progressive respiratory failure. There has been tremendous progress in LAM in the past decade, including a rich molecular understanding of disease pathogenesis, development of a diagnostic and prognostic biomarker, and the discovery of a treatment. The randomized controlled Rare Lung Disease Consortium (RLDC) Multicenter International LAM Efficacy of Sirolimus (MILES) Trial (Sponsor-FXM, IND 71,340) demonstrated that mTOR inhibition with sirolimus is an effective suppressive therapy for LAM, stabilizing lung function, functional performance, and quality of life in women with abnormal lung function. Side effects due to sirolimus were common in MILES, although SAEs were balanced in the sirolimus and placebo groups. The beneficial effects of sirolimus waned when the drug was held in the second year of the trial. Although the primary eligibility criterion was forced expiratory volume in 1 second (FEV1) ≤ 70%, enrolled MILES patients had more advanced respiratory impairment, with about half of lung function remaining (on average), limiting the generalizability of the findings to mild disease. Fear of toxicities and life long therapy lead most clinicians and patients to wait until lung function becomes abnormal before initiating sirolimus therapy to stabilize the damaged lung. This approach is suboptimal and inadequate. The Multicenter Interventional LAM Early Disease Trial (MILED) is a phase III, randomized, placebo-controlled trial to determine if early, long term (2 yr), low dose (1 mg/day) sirolimus treatment of patients with well-preserved lung function will safely prevent disease progression. Sixty patients with normal FEV1 (FEV1>70%) will be enrolled and randomized to 1 mg/day sirolimus or placebo, and followed for 2 years with pulmonary function testing every 4 months. The primary endpoint will be the between-group (placebo vs. sirolimus) difference in the rate of change in FEV1 (in liters). Secondary endpoints will include between group differences in adverse events, forced vital capacity, lung volumes, diffusing capacity, serum VEGF-D, and early airflow obstruction assessed using hyper-polarized gas MRI. The study will be conducted using the infrastructure created for the RLDC, using the Rare Lung Disease Clinic Network, which is currently following over 1200 U.S. LAM patients and conducting the TRAIL trial. The LAM Foundation will be an integral partner and will assist with study recruitment and patient participation. Data will be managed by the University of South Florida Data Management and Coordinating Center. Successful completion of these aims will define the safety and efficacy of low dose sirolimus in patients with normal lung function, and determine if sirolimus can be used to prevent disease progression to symptomatic stages.

多中心介入淋巴管肌瘤病早期疾病试验(Miled试验) 项目摘要 淋巴管肌瘤病(LAM)是一种女性低度转移性肿瘤，由活化引起 导致肺囊性破坏的mTOR途径突变。良性的出现、突变 具有平滑肌样LAM细胞的浸润性肺组织来自未知来源，并执行 导致囊肿形成、复发性气胸、乳糜性胸腔积液和 进行性呼吸衰竭。在过去的十年中，LAM取得了巨大的进步，包括 对疾病发病机制的丰富分子理解，诊断和预后生物标记物的发展， 以及一种治疗方法的发现。随机对照罕见肺病联合体(RLDC)多中心研究 西罗莫司(Miles)试验(赞助商-FXM，IND 71,340)的国际LAM疗效表明，mTOR 西罗莫司抑制LAM是一种有效的抑制疗法，稳定了肺功能， 肺功能异常的妇女的表现和生活质量。西罗莫司的副作用是 虽然西罗莫司组和安慰剂组的SAE是平衡的，但在里程数中很常见。的有益影响 当西罗莫司在试验的第二年被扣留时，西罗莫司的作用减弱了。尽管主要的资格标准 1秒用力呼气量(FEV1)≤为70%，入选英里数患者进展率更高 呼吸损害，约有一半的肺功能剩余(平均)，限制了 发现到轻度疾病。对毒性的恐惧和终生治疗导致大多数临床医生和患者等到肺 在开始西罗莫司治疗以稳定受损的肺之前，功能会变得异常。这种方法是 次优和不足。多中心介入LAM早期疾病试验(MILD)是第三阶段， 随机、安慰剂对照试验，以确定早期、长期(2年)、低剂量(1 mg/d)西罗莫司 对肺功能保存良好的患者进行治疗将安全地防止疾病的进展。60名病人 FEV1(FEV1和GT；70%)正常的患者将入选并随机服用1毫克/天的西罗莫司或安慰剂，然后跟随 连续2年，每4个月进行一次肺功能检查。主端点将是组之间 (安慰剂与西罗莫司)FEV1变化率(升)的差异。次要终端将包括 两组在不良事件、用力肺活量、肺容量、弥散量、血清 血管内皮生长因子-D和超极化气体磁共振评估早期气流阻塞。将进行这项研究 使用为RLDC创建的基础设施，使用罕见肺病诊所网络，该网络目前 跟踪1200多名美国LAM患者并进行试验试验。LAM基金会将是一个不可或缺的 合作伙伴，并将协助研究招募和患者参与。数据将由大学管理 南佛罗里达数据管理和协调中心。这些目标的成功实现将确定 小剂量西罗莫司对肺功能正常患者的安全性和有效性，并确定西罗莫司是否可以 用于防止疾病进展到有症状的阶段。